Loading...
Market
What will be the outcome of Cassava Sciences' detailed results presentation of Simufilam trial by end of 2025?
2
Resolution / Starting Odds
Results lead to renewed interest • 25%
Results confirm initial failure • 25%
Mixed reception from the scientific community • 25%
No significant impact • 25%
Reports from the medical meeting or official publications of the trial results
Story
Cassava's Simufilam Fails Phase 3 Alzheimer's Trial; Company Discontinues Trials, Shares Plunge 85%
Nov 25, 2024, 12:55 PM
Cassava Sciences announced that its Alzheimer's drug, Simufilam, failed to meet co-primary, secondary, and exploratory endpoints in the Phase 3 ReThink-ALZ trial. The study showed that Simufilam did not demonstrate a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease. Despite Simufilam demonstrating an overall favorable safety profile, the company plans to discontinue the second Phase 3 ReFocus-ALZ trial and the Open Label Extension study. Following the announcement, trading of Cassava Sciences' stock was halted, and the stock price dropped by over 85% pre-market. The company plans to present detailed results at a future medical meeting.
View original story
Similar markets
Successful with measurable cognitive improvement • 25%
Partially successful with some cognitive improvement • 25%
Unsuccessful with no cognitive improvement • 25%
Trial canceled or postponed • 25%
Favorable ruling for Cassava Sciences • 25%
Unfavorable ruling for Cassava Sciences • 25%
Settlement • 25%
Case dismissed • 25%
New Alzheimer's drug candidate announced • 25%
Focus shifts to different therapeutic area • 25%
Company gets acquired • 25%
Continues current operations without major changes • 25%
Cassava Sciences wins the lawsuits • 25%
Cassava Sciences settles the lawsuits • 25%
Cassava Sciences loses the lawsuits • 25%
Lawsuits are dismissed • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Profitable • 25%
Break-even • 25%
Loss-making but stable • 25%
Facing financial distress • 25%
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Successful with minimal efficacy • 25%
Unsuccessful • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trials halted • 25%
Revenue increases by 10% or more • 25%
Revenue stays within 10% of current levels • 25%
Revenue decreases by 10% or more • 25%
Cassava Sciences reports a loss • 25%